Dannecker Gunther E, Quartier Pierre
Department of Pediatric Rheumatology, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany.
Horm Res. 2009 Nov;72 Suppl 1:4-12. doi: 10.1159/000229757. Epub 2009 Nov 27.
The term juvenile idiopathic arthritis (JIA) describes a clinically heterogeneous group of arthritides. The onset in all subgroups is before 16 years of age, but each group presents with different clinical signs and symptoms. The cause of the disease is unknown, but both genetic and environmental factors are believed to be involved. Management of the disease has greatly improved in recent years due to advances in pharmacologic treatment options (especially with new biologic agents) and the prognosis for patients is better than ever before. However, none of the available drugs has a curative potential. This review provides an overview on the classification and the clinical symptoms of the defined subgroups of JIA as well as pharmacotherapies for it.
Treatment of children with JIA is challenging and complex. Since lengthy therapy might be necessary, a multidisciplinary pediatric rheumatology team is crucial for optimal treatment. Although a cure is unknown at this time, adequate treatment aims to preserve function of the joints as well as normal childhood development.
青少年特发性关节炎（JIA）一词描述了一组临床异质性关节炎。所有亚组的发病年龄均在16岁之前，但每组表现出不同的临床体征和症状。该病病因不明，但遗传因素和环境因素均被认为与之相关。近年来，由于药物治疗选择（尤其是新型生物制剂）的进展，该病的管理有了很大改善，患者的预后也比以往任何时候都要好。然而，现有的药物均无治愈潜力。本综述概述了JIA特定亚组的分类、临床症状及其药物治疗。
JIA患儿的治疗具有挑战性且复杂。由于可能需要长期治疗，多学科儿科风湿病团队对于优化治疗至关重要。虽然目前尚无法治愈，但充分治疗旨在保留关节功能以及正常的儿童发育。
